Takeda Pharmaceutical Co. Ltd.’s ambitions of becoming a major global Japan-based pharma company could take another turn if it decides to confirm an offer for Shire PLC, which would open up new frontiers in rare diseases and further build out its limited late-stage pipeline.
But any such move also appears to go against some of the past signals and stated intentions of Japan’s largest pharma firm, raising questions around the reasons behind any formal bid for the UK-based